Our study addresses this gap by presenting a structure-guided design strategy for cyclic peptide inhibitors, culminating in the identification of PD-1-0520 as a potent, multi-functional agent capable of disrupting the PD-1/PD-L1 interaction and restoring anti-tumor immunity [14]. The gene discussed is PDCD1; the disease is neoplasm.